Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
LY2780301
i
Other names:
LY2780301
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Eli Lilly
Drug class:
AKT inhibitor, p70S6K inhibitor
Related drugs:
‹
capivasertib (37)
MK-2206 (27)
RG7440 (27)
chidamide (23)
LY294002 (7)
TAS-117 (7)
pexidartinib (6)
ONC201 (5)
DIACC3010 (5)
GSK690693 (3)
enzastaurin (3)
GDC-0084 (3)
CCT128930 (2)
SBI-756 (2)
UCN-01 (1)
DFN-529 (1)
EC-70124 (1)
SBI-726 (1)
nelfinavir (1)
D21266 (1)
CBL0102 (1)
LAE003 (1)
A 443654 (0)
AT7867 (0)
HV-107 (0)
antroquinonol (0)
MKC-1 (0)
SR13668 (0)
TAS0612 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
PBI-05204 (0)
NV06 (0)
PX 866 (0)
PTX-200 (0)
capivasertib (37)
MK-2206 (27)
RG7440 (27)
chidamide (23)
LY294002 (7)
TAS-117 (7)
pexidartinib (6)
ONC201 (5)
DIACC3010 (5)
GSK690693 (3)
enzastaurin (3)
GDC-0084 (3)
CCT128930 (2)
SBI-756 (2)
UCN-01 (1)
DFN-529 (1)
EC-70124 (1)
SBI-726 (1)
nelfinavir (1)
D21266 (1)
CBL0102 (1)
LAE003 (1)
A 443654 (0)
AT7867 (0)
HV-107 (0)
antroquinonol (0)
MKC-1 (0)
SR13668 (0)
TAS0612 (0)
NSC311152 (0)
inhibitors of the PI3K/AKT/mTOR pathway (0)
PBI-05204 (0)
NV06 (0)
PX 866 (0)
PTX-200 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 negative
HER2 Negative Breast Cancer
HER-2 negative
HER2 Negative Breast Cancer
LY2780301
Sensitive: C2 – Inclusion Criteria
LY2780301
Sensitive
:
C2
LY2780301
Sensitive: C2 – Inclusion Criteria
LY2780301
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login